FGFR Inhibitor Shows Preclinical Activity in Breast Cancer

Video
Conference|American Association for Cancer Research Annual Meeting (AACR)

This video highlights preclinical activity of a novel FGFR inhibitor that has been tested alone and in combination with antihormonal therapy in breast cancer cell lines.

In this video, Dominik Mumberg, PhD, of Bayer AG in Berlin, highlights preclinical activity of a novel FGFR inhibitor that has been tested alone and in combination with antihormonal therapy in breast cancer cell lines.

The data were presented at the 2017 American Association for Cancer Research (AACR) Annual Meeting, held April 1–5 in Washington, DC.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
Related Content
Elranatamab Triplet Induces Early and Deep Responses in Newly Diagnosed MM

Elranatamab Triplet Induces Early and Deep Responses in Newly Diagnosed MM

Ariana Pelosci
June 16th 2025
Article

The MagnetisMM-6 trial showed that elranatamab plus daratumumab and lenalidomide yielded an ORR of 97.3% in transplant-ineligible multiple myeloma.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Low rates of early relapse in both arms of the phase 3 IsKia trial support the efficacy of carfilzomib in this newly diagnosed multiple myeloma setting.

Isatuximab Combination Significantly Sustains MRD Negativity in NDMM

Russ Conroy
June 16th 2025
Article

Low rates of early relapse in both arms of the phase 3 IsKia trial support the efficacy of carfilzomib in this newly diagnosed multiple myeloma setting.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Quarterly MRD Monitoring After Daratumumab Allows Relapse Detection in Multiple Myeloma

Quarterly MRD Monitoring After Daratumumab Allows Relapse Detection in Multiple Myeloma

Ariana Pelosci
June 14th 2025
Article

Results of the PREDATOR-MRD trial found that daratumumab could help predict MRD response for patients with multiple myeloma.

36 Expert Perspectives in the Management of Breast Cancer Brain Metastases: A Survey of 32 International Specialists

36 Expert Perspectives in the Management of Breast Cancer Brain Metastases: A Survey of 32 International Specialists

Sarah Hertrich;Komal Jhaveri;Javier Cortés, MD;Sara Hurvitz, MD;Brian Moss;Chloe Gianatasio
June 14th 2025
Article